Truist Financial
JSPR icon

Truist Financial’s Jasper Therapeutics JSPR Stock Holding History

Truist Financial’s Portfolio JSPR Stock Details JSPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,125
Closed -$89K – 2758
2021
Q4 		$89K Buy
+1,125
New +$105K ﹤0.01% 2681

Other funds holding JSPR

QUSVM
Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Truist Financial's JSPR Position: Q1 2022 in Review

Truist Financial sold out of Jasper Therapeutics (JSPR) in Q1 2022, closing a stake of 1,125 shares — an estimated $89K sold.

Truist Financial first reported a position in JSPR in Q4 2021 and held it in 1 quarter. The position peaked at $89K in Q4 2021. 24 funds tracked by Wall St. Rank hold JSPR as of Q1 2022.

  • Truist Financial reported no remaining Jasper Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Truist Financial sold 1,125 Jasper Therapeutics shares in Q1 2022, an estimated $89K.
  • Truist Financial first reported a position in Jasper Therapeutics in Q4 2021 and held it in 1 quarter.
  • Truist Financial's Jasper Therapeutics position peaked at $89K in Q4 2021.
  • 24 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q1 2022.

Based on Truist Financial's 13F filing for Q1 2022, filed 22 Apr 2022.